Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome.

Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J (2015) 0.83

Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart (2016) 0.75

Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation (2006) 3.62

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2004) 3.47

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2005) 3.25

Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol (2007) 2.66

Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation (2005) 2.49

Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J (2007) 2.38

Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation (2011) 2.34

Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. Stroke (2006) 2.21

Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg (2007) 1.76

Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv (2008) 1.76

Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol (2002) 1.63

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv (2012) 1.57

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol (2008) 1.56

High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol (2004) 1.52

Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med (2006) 1.46

Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg (2005) 1.44

Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Catheter Cardiovasc Interv (2010) 1.41

Contemporary issues on clopidogrel therapy. Intern Emerg Med (2009) 1.39

Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. Am J Cardiol (2011) 1.17

Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 1.10

Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol (2006) 1.08

Giant left ventricular pseudoaneurysm complicating an acute myocardial infarction in patient with previous cardiac surgery: a case report. J Cardiovasc Med (Hagerstown) (2009) 1.02

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 0.97

Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol (2008) 0.95

Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J (2006) 0.93

Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol (2011) 0.93

Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol (2011) 0.90

Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. Ann Thorac Surg (2003) 0.88

Identifying factors that predict the choice and success rate of radial artery catheterisation in contemporary real world cardiology practice: a sub-analysis of the PREVAIL study data. EuroIntervention (2010) 0.88

Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. Catheter Cardiovasc Interv (2011) 0.87

Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 0.86

Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. J Am Coll Cardiol (2013) 0.86

Dissecting intramyocardial hematoma masquerading as a pseudoaneurysm of left ventricular free wall: an unusual case of myocardial rupture. Catheter Cardiovasc Interv (2006) 0.86

High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol (2011) 0.85

High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010) 0.85

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol (2012) 0.84

Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol (2005) 0.83

Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol (2005) 0.82

Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol (2002) 0.81

Statin loading for acute coronary syndromes. Curr Opin Cardiol (2010) 0.81

Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol (2010) 0.81

Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis (2007) 0.80

Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study. Int J Cardiol (2012) 0.79

Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). Am J Cardiol (2013) 0.79

Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart (2006) 0.79

Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010) 0.78

Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. Int J Hypertens (2011) 0.78

Hand-held echocardiography in the setting of pre-operative cardiac evaluation of patients undergoing non-cardiac surgery: results from a randomized pilot study. Int J Cardiovasc Imaging (2015) 0.78

[The role of endothelial dysfunction in the pathogenesis and in clinical practice of atherosclerosis. Current evidences]. Recenti Prog Med (2005) 0.78

Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials. Crit Pathw Cardiol (2010) 0.77

Plasma concentrations of interleukin-2 soluble receptor in mild ischaemic left ventricular dysfunction. Eur J Heart Fail (2003) 0.77

Prevention of myocardial damage during coronary intervention. Cardiovasc Hematol Disord Drug Targets (2006) 0.77

Inflammatory markers and coronary interventions: a potentially useful follow-up modality after stenting. Catheter Cardiovasc Interv (2002) 0.77

Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). Am J Cardiol (2013) 0.77

Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Cardiovasc Med (Hagerstown) (2010) 0.76

Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum Immunol (2011) 0.76

Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets (2013) 0.76

Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Am J Cardiol (2013) 0.76

Prasugrel versus clopidogrel. N Engl J Med (2008) 0.76

Simvastatin reduces CD40 expression in an experimental model of early arterialization of saphenous vein graft. J Surg Res (2006) 0.76

Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis (2002) 0.76

Standard- vs high-dose clopidogrel after percutaneous coronary intervention. JAMA (2011) 0.76

Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy? J Am Coll Cardiol (2012) 0.75

Statins and percutaneous coronary intervention. Eur Heart J (2005) 0.75

Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention. Am J Cardiol (2008) 0.75

Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. Catheter Cardiovasc Interv (2010) 0.75

Prognostic role of platelet reactivity in patients with acute coronary syndromes. Cardiol Rev (2014) 0.75

Atorvastatin for reduction of myocardial damage during angioplasty trials. J Cardiovasc Med (Hagerstown) (2010) 0.75

[Echocardiography in patent foramen ovale]. G Ital Cardiol (Rome) (2006) 0.75

The use of functional tests and planned coronary angiography after percutaneous coronary revascularization in clinical practice. Results from the AFTER multicenter study. Int J Cardiol (2008) 0.75

Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy. J Cardiovasc Med (Hagerstown) (2011) 0.75

Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis. J Thromb Thrombolysis (2008) 0.75

The risks and benefits of drug-eluting stents in the setting of STEMI. Curr Cardiol Rep (2008) 0.75

Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. J Cardiovasc Transl Res (2013) 0.75

[Transcatheter cell therapy of heart failure: state of the art]. G Ital Cardiol (Rome) (2006) 0.75

[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention]. Ital Heart J Suppl (2005) 0.75

Percutaneous closure of patent foramen ovale in a patient with situs viscerum inversus. J Cardiovasc Med (Hagerstown) (2013) 0.75

Percutaneous closure of a pulmonary arteriovenous malformation in young patient with cryptogenic stroke. JACC Cardiovasc Interv (2013) 0.75

Statins and their role in pre-percutaneous coronary intervention. Curr Cardiol Rep (2010) 0.75

Curriculum and syllabus for Interventional Cardiology subspecialty training in Europe. EuroIntervention (2006) 0.75

A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. EuroIntervention (2010) 0.75

Percutaneous coronary interventions and statins therapy. Ther Adv Cardiovasc Dis (2008) 0.75

Transapical closure of paraprosthetic mitral leak in a patient with inferior vena cava interruption and azygos continuation. J Cardiovasc Med (Hagerstown) (2015) 0.75